Series A  ·  2026
← → navigate  ·  G overview  ·  ESC close
Slide Navigator
G · ESC TO CLOSE
Series A Investment Opportunity
Lumati

Building the
Infrastructure of the
Longevity Economy

An intelligent ecosystem synchronizing personal vitality, clinical excellence, and global impact into one unified system.

LUMATI HOLDINGS, INC. · CONFIDENTIAL · MARCH 2026
The Opportunity

Modern Life Is Making Us Sicker

Chronic disease is accelerating globally. The population over 50 has grown 400% since 1970, yet healthcare remains reactive — treating symptoms instead of root causes. The longevity market is exploding.

GLOBAL AGING
1.8B+
People aged 50+ globally
400% increase since 1970. By 2050, 2.1B.
+400%
DEEP DIVE ↗
US MARKET
120M+
Americans over 50
$7.6T spending power. Seeking longevity solutions.
36% of US
DEEP DIVE ↗
LONGEVITY MARKET
$25B → $127B
5x projected growth
Fastest-growing segment. Preventive, root-cause medicine.
5.1x
DEEP DIVE ↗
THE CRISIS — WHY NOW
60%
of adults have a chronic disease
$4.5T
annual US healthcare spend
90%
spent on symptoms, not cures
74%
of deaths from chronic conditions
0.04%
of spend goes to prevention
TAM
SAM
SOM
$890M
$127B TAM — Global Longevity & Anti-Aging
$9.3B SAM — Addressable across 7 product lines
$890M SOM — 2030 target · 9.6% SAM capture
Blood Purification $3.0B Longevity Clinics $2.9B Digital Health $1.1B Supplements $1.1B Devices $0.6B Diagnostics $0.6B
Sources: UN World Population Prospects 2024; AARP Longevity Economy Report 2024; Grand View Research Longevity & Anti-Aging Market 2024; CDC Chronic Disease Prevention 2024; CMS National Health Expenditure Data 2024.
The Vision

1 Billion Lives by 2035

Five interconnected layers. One unified ecosystem. From flagship to your home.

PREVENTION & OPTIMIZATION
ACCELERATED RECOVERY
CHRONIC CONDITIONS
Lumati
FLAGSHIP
Destination Hubs
POWERED CLINICS
Licensed Partners
RECHARGE NETWORK
Portal Locations
LUMATI HOME
Equipment & Supplements
EDUCATION & APP
AI-Powered Health OS
CLICK ANY NODE FOR DETAILS
THE ECOSYSTEM
Lumati Flagship
Full-service flagship centers
Powered Clinics
Licensed clinical partners
Recharge Network
Portal locations worldwide
Lumati Home
Equipment & supplements
Education & Lumi App
AI-powered health OS
5
LAYERS
371
CLINICS BY 2030
2,488
PORTALS
131K
PATIENTS
$890M
2030 REVENUE
The Science

8 Cellular Targets · 5 Principles

Hypoxia
Cellular oxygen deprivation
LEARN MORE ↗
Mitochondrial Dysfunction
Impaired energy production
LEARN MORE ↗
Misfolding Proteins
Aggregation & toxicity
LEARN MORE ↗
Impaired Autophagy
Cellular recycling failure
LEARN MORE ↗
Shortened Telomeres
Accelerated aging clock
LEARN MORE ↗
Chronic Inflammation
Immune dysregulation
LEARN MORE ↗
Apoptosis & Senescence
Zombie cells accumulate
LEARN MORE ↗
Epigenetic Drift
Gene expression decay
LEARN MORE ↗
ANCIENT WISDOM · MODERN SCIENCE

For millennia, nature provided the blueprint for healing. Lumati translates these timeless forces into precision clinical technology — restoring what modern life has disrupted.

Light
Sunlight to Red Light+
EXPLORE ↗
💧
Water
Living water & molecular H₂
EXPLORE ↗
Sound
Ancient bowls to neural entrainment
EXPLORE ↗
Frequency
Earth’s pulse to PEMF
EXPLORE ↗
🌱
Earth
Nutrition, grounding & homeostasis
EXPLORE ↗
Clinical Framework

Four Steps to Cellular Restoration

A proprietary protocol that reads, removes, rebuilds, and nourishes at the cellular level.

NLS
STEP 1

READ

Real-Time Health Assessment

Whole body NLS scan, 3D dental imaging, metabolic testing, and 10+ diagnostic tools create a complete digital health baseline.

CLICK FOR DETAILS ↗
HemoDetox
STEP 2

WEED

Subtractive Medicine

OroDetox, HemoDetox blood filtration, and molecular hydrogen therapy remove pathogens, toxins, and heavy metals before restoration.

CLICK FOR DETAILS ↗
Exosomes
STEP 3

SEED

Targeted Cellular Support

Exosomes, HCT/P cellular regeneration, oral peptides, and targeted supplements rebuild at the cellular level.

CLICK FOR DETAILS ↗
Recharge Portal Room
STEP 4

FEED

Ongoing Cellular Nourishment

Weekly 15-min Recharge Portal sessions: Red Light+, PEMF, molecular hydrogen, sound therapy, and bioresonance.

CLICK FOR DETAILS ↗
Published Case Study · Third-Party Validated

The Science Behind the Portal

mescreen™ Mitochondrial Function Blood Test · Developed at UC San Diego & NASA · 100-Day Controlled Study

+89%
Mitochondrial Energy · 60 days
+107%
Metabolic Efficiency Ratio · 30 days
+21%
Retained After 40-Day Washout
MITOCHONDRIA ENERGY SCORE
3x/week Recharge Portal Sessions
38
Day 0
Low
51
Day 30
Optimal
72
Day 60
High
46
Day 100
40d off
KEY FINDING
Energy remained in Optimal range 40 days after stopping — suggesting lasting mitochondrial adaptation via AMPK/SIRT1 activation and Nrf2-mediated ROS reduction.
Hamblin 2016 (Red Light) · Ohta 2012 (H₂) · Lau 2012 (Micro-Impact) · López-Otín 2013 (Hallmarks of Aging)
Recharge Portal
Recharge Portal
15 min · All modalities
Portal Session
RED LIGHT+ H2 VIBRATION SOUND BIORESONANCE
TARGETED HEALTH IMPROVEMENTS
Longevity
Sleep & Stress
Fatigue
Mental Health
Brain Fog
Injury Recovery
Chronic Pain
Vision
Fertility
Diabetes
Auto Immune
Cancer Support
X
XPRIZE HEALTHSPAN · $101M COMPETITION
Recharge Portal Selected for ASU Research Protocol
Smart Fit Method — exclusive fitness partner for Arizona State University’s XPRIZE team — has integrated the Lumati Recharge Portal into its age-reversal protocol. Goal: reverse biological age 10–20 years in one year.
“I feel sharper, sleep deeper, think clearer.”
PORTAL USER
VIEW FULL STUDY ↗
Clinical Network

Three-Tier Licensing Model

1
Level One · Outpost

Equipment Only

AOV$80K
COGS60%
Net40%
2
Level Two · Spokes

Equipment + Protocols

Upfront$25K
Monthly$10K+
Rev Share5%
3
Level Three · Hubs

Full Stack + Equity

Ownership10%+
Full StackYes
EquityAligned
$10M+Pipeline
50+Clinics in Pipeline
10–20Live by Q4 2026
Subtractive Medicine

Remove Before You Restore

While others focus on adding — supplements, hormones, stem cells — Lumati leads the subtractive medicine movement: clearing the body’s terrain first.

OroDetox Procedure
ORODETOX

Cleaning the Mouth

Hidden oral infections driving heart disease, cancer & autoimmune conditions

Cavitation Surgery — remove necrotic jawbone & hidden infections
Safe Extraction — mercury amalgam & root canal removal
Cone-Beam CT — 3D imaging reveals what X-rays miss
Systemic Integration — dental + functional medicine
WHY IT MATTERS
Oral bacteria enter the bloodstream 24/7. Studies link dental infections to 94% of chronic disease patients.
HemoDetox Treatment
HEMODETOX
#1 REVENUE DRIVER

Cleaning the Blood

Advanced blood filtration — IP-backed & scalable across hospital networks

Dual-Target Filtration — metals, PFAS, microplastics + pathogens, CTCs
200+ Treatments — autoimmune, chronic infections & performance
Clinical Trials — Long COVID & Lyme, USA hospital launch
IP Strategy — proprietary filter tech for defensible moat
82%
of 2030 Revenue
118
Hospitals
$731M
2030 Rev
THE SILENT BURDEN
Everyday exposure to toxins, plastics & pathogens accelerates aging. The body cannot clear these alone.
$89B
Blood Purification TAM
133M
Chronic Disease (US)
Precision Health Operating System

Lumi: Your Personalized Digital Twin

v1.0 LIVE IN APP STORE | v2.0 · 2026

The future of longevity is personalized. No two bodies are the same — and no two protocols should be either. Lumi learns your unique biology in real-time, building a precision health model that adapts as you change. From biomarker tracking to AI-driven protocol adjustments, one intelligent platform transforms raw data into personalized action — clinic to home, cell to system, diagnosis to daily life.

Precision Protocols
Your protocol adapts to your data — AI adjusts supplement timing, dosing, and sequencing based on your unique biology
Predictive Intelligence
Longitudinal biomarker tracking with AI that spots patterns before symptoms appear — prevention, not reaction
Personalized Education
Content tailored to your health profile — learn why each modality matters for your specific cellular needs
Adaptive Nutrition v2
AI-powered meal analysis calibrated to your metabolic profile, deficiencies, and wellness goals
Flagship Clinical Centers

The Lumati Flagship

Where the full READ / WEED / SEED / FEED protocol comes to life. Physician-led, research-driven clinical centers delivering the complete Lumati experience.

Lumati Flagship Tijuana — NewCity Medical Plaza
OPERATIONAL
CLICK TO EXPLORE ↗

Tijuana, Mexico

Opened Oct 2024

First-of-its-kind clinical center delivering the complete 4-step detoxification and regeneration protocol. Full-service physician oversight with 30+ therapeutic modalities.

Full Protocol 30+ Modalities Physician-Led Clinical Research
Lumati Flagship Las Vegas
COMING 2026
CLICK TO EXPLORE ↗

Las Vegas, Nevada

Opening 2026

Premier longevity destination in the entertainment capital. Flagship wellness center bringing the complete Lumati protocol to high-net-worth individuals and medical tourism visitors.

Flagship Center Luxury Setting Full Protocol High-Net-Worth
30+
MODALITIES
4
STEP PROTOCOL
$45K
AVG PROGRAM
5-14
DAY PROGRAMS
Hub
TRAINING CENTER
Consumer Ecosystem

Lumati Home

Clinical-grade products & app-connected protocols — compounding results between clinic visits.

Lumati Green, Red & Gold
SUPPLEMENTS
Lumati Red · Green · Gold
Clinical-grade nutraceuticals prescribed in-clinic, delivered monthly via auto-ship subscription.
Recurring Revenue 83% Gross Margin
Lumati Red Light+ LED Face Mask
DEVICES
Red Light+ Face Mask
630nm + 850nm · LED photobiomodulation
Molecular Hydrogen
DEVICES
Molecular Hydrogen
H₂ water, inhalation & immersion therapy
Lumati Detect Microplastics Test Kit
DIAGNOSTICS
Lumati Detect
At-home saliva test kit · results sync to Lumi
Lumi App — Connected Ecosystem
CONNECTED ECOSYSTEM
Lumi App
BioMetrics · BioReset · BioRecharge · Marketplace
9+
PRODUCTS
5
CATEGORIES
83%
BEST GM
24/7
APP CONNECTED
shop.lumati.com
SHOP NOW ↗
GTM & Traction

Flywheel In Motion

Revenue live. Clinics deploying. Portals shipping. Every deal signed accelerates the next.

$5.7M
2.4x YoY
2025 Revenue (Live)
$1.0M
’23
$2.7M
’24
$5.7M
’25
50+
Clinic Pipeline
2,488
Portal Target (2026)
200+
HemoDetox Treatments
GLOBAL NETWORK
2025
12
Clinics
450
Patients
1
Hospitals
12
Portals
2025 2026 2027 2028 2029 2030
NETWORK FLYWHEEL
🚀
DEPLOY
Portals & Clinics
🩹
TREAT
Patients & Outcomes
🧠
DATA
AI Gets Smarter
Lumati
📈
REFER
Network Grows
🛒
eCOMM
Supplements & Home
📱
APP
Lumi Engagement
Each cycle accelerates the next — compounding impact across every channel
EXECUTION MILESTONES
Achieved 2026 Roadmap
Founded
’22 / Lumati ’24
1st Portal
Nov ’24
$5.7M Rev
Dec ’25
XPRIZE
Feb ’26
Resort Partners
Jan–Feb ’26
Detect: Cancer
Mar ’26
Fairmont CC
Apr ’26
Function Health
May ’26
Portal V2
May ’26
LV Launch
Jul ’26
Competitive Moat

The Lumati Fortress

Six powerful moats protect the ecosystem. No single competitor can replicate the full stack — and network effects compound with every clinic, portal, and patient added.

Lumati
ECOSYSTEM
🏥
Flagship
Flagship hubs
Powered Clinics
50+ pipeline
Recharge
2,488 portals
🏠
Home
Consumer HW
📱
Lumi App
AI health OS
SIX POWERFUL MOATS
🔐
Proprietary Protocol IP
READ/WEED/SEED/FEED — years of R&D, impossible to reverse-engineer
DETAILS ↗
🌐
Compounding Network Effects
Each clinic & portal amplifies value — partners become recruiters
DETAILS ↗
🧠
AI Data Flywheel
Lumi captures every interaction — new entrants start from zero
DETAILS ↗
🔒
Deep Switching Costs
Clinics embed protocols, software, supply chain — can’t leave
DETAILS ↗
Regulatory & Clinical Moat
HIPAA, IRB studies, XPRIZE — clinical evidence takes years
DETAILS ↗
🏦
Capital & Infrastructure
$40M+ to replicate — hardware + software + clinical ops
DETAILS ↗
NETWORK EFFECT IN ACTION — KEY REFERRAL PARTNERS
Stephen A. Smith
Media & Celebrity
TAP FOR BIO ↗
Gary Brecka
Biohacking / 77M reach
TAP FOR BIO ↗
Dr Mark Hyman
Functional Medicine KOL
TAP FOR BIO ↗
Ben Greenfield
Fitness & Longevity
TAP FOR BIO ↗
Steve Harvey
Media & Lifestyle
TAP FOR BIO ↗
Fountain Life
Longevity Clinic Network
TAP FOR BIO ↗
ExThera Medical
HemoDetox Technology
TAP FOR BIO ↗
Dr Minkoff
Integrative Medicine Pioneer
TAP FOR BIO ↗
Competitive Landscape

The Only Fully Integrated Play

Competitors address fragments. Lumati owns the full stack — protocol, hardware, software, clinical network, and consumer experience.

CAPABILITY
Lumati
Full Ecosystem
Restore
Hyper Wellness
NextHealth
Longevity Clinic
WHOOP
Wearable
Oura
Wearable
10X Health
Biohacking
🔐 Proprietary Protocol
⚡ Clinical Hardware Partial Partial Partial
🏠 Consumer Hardware
📱 AI Health OS / App
🏥 Clinic Network Partial
🏦 Flagship Center
🧠 Published Clinical Data Partial Partial
🌐 Data Flywheel / AI Partial Partial
8/8
Lumati — Full Stack Integration
The only company that owns protocol design, clinical hardware, consumer hardware, AI software, clinical network, flagship center, and data flywheel — with published clinical data in progress.
2/8
Nearest Competitor
No competitor covers more than 2–3 dimensions
SEE MOAT DETAILS ↗

Executive Team & Advisors

BUSINESS LEADERSHIP
David Perez
Co-Founder & CEO
45+ years founding ventures
Founder
Ruta Laukien
Chairwoman
GrayBella Capital, Duke JD/MBA
Governance
Samuel Whiting
Chief Strategy Officer
WHOOP, UCLA Sports Medicine
Strategy
Gunnar Link
Chief Financial Officer
M&A, 3 company sales
Finance
Erol Erturk
Chief Technology Officer
10+ yrs, Purdue, AI/software
Technology
Geylin Castillo
Co-Founder
Hydrate Wellness 2022
Founder
Paul Meek
President Hospitality
28 yrs, 200+ projects, $2B+
Hospitality
Drew Stacy
EVP Operations
2 decades hotel leadership
Operations
Darrell Edwards
GM Patient Advocacy
40+ yrs, healthcare ops exec
Patient Ops
MEDICAL LEADERSHIP
Dr Christos Stavropoulos
Chronic Medical Dir.
Cardiothoracic, 25+ yrs
Medical
Dr Daniel Roney
Longevity Medical Dir.
25+ yrs, cancer survivor
Medical
Dr Guillermo Castillo
Regenerative Medical Dir.
20+ yrs functional med
Medical
Dr Greg Lane
Clinical Director
Founding member, 31+ yrs
Medical
Governance & Strategic Capital

Board of Directors & Advisors

Seasoned operators, investors, and builders who have scaled companies to billions in enterprise value.

BOARD OF DIRECTORS
CHAIR
Ruta Laukien
Chairwoman
Bear Stearns VP · GrayBella Capital · Duke JD/MBA/LLM
David Perez
Co-Founder & CEO
45+ yrs founding ventures
DR
David Roth
Board Director
Strategic advisor
Eugene Chrinian
Board Director
Founder, Ashley Northeast · 27 Locations
David Kasteler
Board Director
Regen Medicine · 4 Exits · $200M+ Rev
BOARD OF ADVISORS
Lucas Winthrop
COO, Winthrop Wealth · $2.6B AUM
Wylie Aronow
Co-Founder, Yuga Labs / BAYC
Skyler Ditchfield
Co-Founder, GeoLinks · FCC TAC
Todd Wanek
President & CEO, Ashley Furniture
Joe Kudla
Founder & CEO, Vuori
$12B+
COMBINED ENTERPRISE VALUE
155+
COUNTRIES REACHED
NYSE
PUBLIC COMPANY LEADERSHIP
10
DIRECTORS & ADVISORS
$5B+
BRANDS BUILT (VUORI, BAYC)
Financials

The Bridge to $890M

157x
Revenue Growth
’25 → ’30
$218M
2030 Gross Profit
2027
Profitable
PROVEN GROWTH
$1.0M
’23
$2.7M
’24
$5.7M
’25
2.4x avg YoY
12
Clinics
450
Patients
1
Hospital
2030 TARGET
$890M
371
Clinics
131K
Patients
118
Hospitals

Revenue Bridge — Year-Over-Year

HD Portal Equip Clinic
Full Income Statement
5-year P&L with EBITDA & net income
Margin Profile
GM%, EBITDA%, net income trajectory
GROWTH ENGINES
HemoDetox Network
$731M
Scale blood filtration across 371 clinics. ~$2M/clinic. 15% net GM after clinic rev-share (direct treatment margin 80%+). Upside as equipment amortizes and volume improves.
82% of 2030 revenue
Recharge Portal SaaS
$105M
Deploy 2,488 portals at ~$42K/yr. 66% GM — highest-margin recurring engine.
12% of revenue · 49% of non-HD gross margin
Equipment & Supplies
$39M
Capital equipment to network. 67% GM. Margins improve 48% → 67% at scale.
Clinic & Supplements
$15M
Flagship clinic at 83% GM — highest-margin line. Supplements add recurring consumer revenue.
EBITDA WALK
-$1.4M
2025
-$0.1M
2026
$23.7M
2027 ✓
$76.9M
2028
$145.7M
2029
$121.5M
2030
*reinvest yr
*2030 EBITDA reflects ~$24M strategic reinvestment in international expansion (15+ new markets), accelerated R&D pipeline, and Lumati Foundation commitment — prioritizing long-term platform value.
*Based on contracted pipeline, clinic rollout schedule, and conservative patient volume assumptions.
Unit Economics

Revenue & Margin by Division

Five revenue lines — diversified margins, compounding growth
48x
Revenue Growth
’26 → ’30
83%
Best GM
$218M
Gross Profit ’30

Revenue by Division

$ IN MILLIONS
DIVISION 2026 2027 2028 2029 2030 GM%
HemoDetox $13.1 $64.0 $229.1 $524.3 $731.1 15%*
Recharge Portal $1.2 $10.6 $29.2 $59.1 $104.5 66%
Equipment $2.7 $7.6 $14.8 $25.7 $38.6 67%
Clinic $1.7 $2.9 $5.3 $8.5 $11.7 83%
Supplements $0.03 $0.3 $0.8 $1.8 $3.6 36%†
Total $18.6 $85.4 $279.2 $619.4 $889.6 24%
*Net margin after clinic rev-share; direct treatment margin 80%+. †Blended wholesale/marketplace; DTC margin 83%.

Revenue Mix by Year

HD Portal Equip Clinic

2030 Revenue Mix

$890M
Total
HemoDetox 82%
Portal 12%
Equipment 4%
Clinic 1%

2030 Gross Margin

Clinic
83%
Equipment
67%
Portal
66%
Supplements
36%
HemoDetox
15%
%
MARGIN DIVERSIFICATION
HemoDetox is 82% of revenue but only 51% of gross margin. Portal + Equipment + Clinic contribute the other 49% on just 18% of revenue.
SCALE ECONOMICS
Portal margins improve 57%→66% and Equipment 48%→67% as volume scales. Clinic holds steady at 83% — highest-margin line.
$
GROSS MARGIN TRAJECTORY
2030 gross margin of $218M across all lines. Non-HD divisions contribute $106M in margin at 67% avg GM. HD margin has upside as scale improves.
*Revenue by division based on contracted pipeline, clinic rollout schedule, and conservative patient volume assumptions. See data room for full model.
UNIT ECONOMICS

Proven at the Unit Level

Hardware Unit Margins

PRODUCT RETAIL COGS NET GM%
Recharge Pod $130,000 $61,800 $68,200 52.5%
PRO10 Pod $89,900 $46,000 $43,900 48.8%
Recharge Portal $60,000 $23,400 $36,600 61.0%
Dual Panel $69,900 $37,000 $32,900 47.1%
H2 Bath $9,000 $1,800 $7,200 80.0%

GROSS MARGIN BY PRODUCT

H2 Bath
80%
Recharge Portal
61%
Recharge Pod
52.5%
PRO10 Pod
48.8%
Dual Panel
47.1%
$0
Zero CAC
$40.9K
Labs LTV
47–80%
Hardware GM
HEMODETOX TIER LADDER
Margin expands with filter count — upsell drives profitability
1-Filter
26%
3-Filter
55%
5-Filter
65%
Legacy
80%
LABS DIRECT LTV
$40,876 per customer
52 customers × $40.9K avg = $2.13M total revenue
Direct lab services — no intermediary, no channel discount
MEMBERSHIPS & SERVICES
95%
Membership GM
$299 ARPU
83%
Clinic GM
Highest-margin line
82%
Shipping GM
$142K rev
$0
ZERO-CAC ADVANTAGE
100% organic & referral acquisition. No payback period, no burn-to-earn. Every dollar of revenue is real margin.
MARGIN EXPANSION BY TIER
HemoDetox margins expand 26% → 80% via upsell ladder. Higher tiers = higher volume = lower per-unit cost.
$68K
HARDWARE AS ANNUITY
Each Recharge Pod yields $68K margin. Equipment sold once but drives recurring clinic visits, memberships, and supplement revenue.
*Unit margins based on current contracted COGS and retail pricing. See data room for detailed cost breakdowns.
Risk Management

Risks & Mitigations

Proactive risk management across regulatory, operational, and market dimensions.

Regulatory — COFIPRIS Approval
HIGH PRIORITY
Risk: HemoDetox Long Covid clinical trial requires COFIPRIS authorization in Mexico.
Mitigation: Regulatory counsel engaged. Parallel applications in multiple jurisdictions. Existing FDA EUA for Seraph 100 provides regulatory precedent.
Execution — Portal V2 GTM
MEDIUM PRIORITY
Risk: Recharge Portal V2 design and GTM MVP must execute on schedule to hit 2026 deployment targets.
Mitigation: V1 in production across multiple sites. V2 design underway with customer feedback loop. Modular architecture allows incremental rollout.
Channel — Hospitality Rollout
MEDIUM PRIORITY
Risk: Successful hospitality partnership rollout in 2026 is critical for portal placement pipeline.
Mitigation: Alila Marea and La Valle already deployed and generating data. Hotel Del Coronado in pipeline. Proven unit economics de-risk expansion.
Concentration — HD Revenue
MONITORED
Risk: HemoDetox = 82% of projected 2030 revenue. Single-product concentration risk.
Mitigation: Non-HD lines contribute 49% of gross margin on 18% of revenue. Higher-margin divisions de-risk the P&L.
REVENUE
HD 82%
18%
MARGIN
HD 51%
Non-HD 49%
Portal 66%
Equipment 67%
Clinic 83%
REGULATORY ADVANTAGE
ExThera FDA EUA + HIPAA infrastructure + IRB-approved studies provide regulatory moat competitors cannot shortcut.
EXECUTION TRACK RECORD
Founded ’22 (Hydrate Wellness), rebranded Lumati May ’24 → $5.7M revenue by Dec ’25. Portal shipped, app live, 200+ patients treated. Team executes.
DIVERSIFICATION PATH
Five revenue lines, three channels (clinic, hospitality, consumer). Non-HD contributes $106M gross margin at 67% avg GM by 2030 — no single point of failure.
We Seek Partners Who Think in Decades
“We are not building for a quarter.
We are building for generations.”
TIMING
Longevity market inflecting 5x to $127B by 2030. First-mover advantage in integrated protocols is closing fast.
TRACTION
$5.7M revenue, 50+ clinic pipeline, XPRIZE selection, resort partners live. Capital now accelerates a proven flywheel.
MISSION
1 billion lives by 2035. Every month without scale is lives not reached. This capital builds the infrastructure of a movement.
Series A
$40M
Pre-Money: $100M
PRIOR CAPITAL RAISED
Conv. Note $3.7M | SAFEs $4.4M | Total $8.1M

Use of Proceeds

$40M
35% Network Growth
25% Ops & Marketing
20% HemoDetox Trials
20% R&D V2

Where Your Capital Goes

$14M
Network Growth
Deploy 200+ Recharge Portals across hospitality & clinic partners. Scale to 35 clinics by end of 2026.
$10M
Ops & GTM
Brand marketing, sales team expansion, hospitality BD. Target: Fairmont, Dromoland, Las Vegas launches.
$8M
HemoDetox Clinical Trials
Long COVID & Lyme studies. COFIPRIS + parallel US regulatory. HemoDetox USA expansion.
$8M
R&D & Product
Portal V2, Recovery Pods, Molecular H₂ Baths, Lumi App v3, Detect Cancer Test.
CAPITAL POSITION
Total Assets $8.0M | 2025 Revenue $5.7M | Gross Margin 48%
OUR IDEAL PARTNER
Thinks in Decades, Not Quarters
Patient capital for a generational platform — healthcare transformation is not a sprint
Values-Driven, Mission-First
Aligned on impact — 1 billion lives by 2035. 10% pre-tax revenue to Lumati Foundation
Strategic, Not Just Capital
Network, expertise, and conviction — partners who open doors and compound our moat
Conviction Over Consensus
Sees what others miss — integrative medicine will be the standard of care, not the alternative
TARGET RETURN
~10x
2030 REVENUE
$890M
“The best investments are built on shared values.
We choose partners the way we choose protocols —
with intention, integrity, and a long time horizon.
— DAVID PEREZ, FOUNDER & CEO
Lumati

The Infrastructure of the
Longevity Economy Starts Here

One ecosystem. Five revenue engines. A mission to impact 1 billion lives by 2035.

David Perez
Founder & CEO
+1 (858) 414 4811
Samuel Whiting
Chief Strategy Officer
+1 (413) 262 9257
Lumati Foundation: 10% Pre-tax Revenue to community programs
Patient. Principled. Transformational.
Legal

Disclaimer

The following financial models and/or projections have been used by the management of Lumati Holdings, Inc. (the “Company”) in planning the future operations of the Company. They are necessarily speculative in nature and should not be viewed as projections of the future financial performance of the Company. While management believes that the objectives of the pitch deck have been prepared in good faith, based upon existing conditions and reasonable assumptions, there can be no assurance that such objectives will be realized. The actual results of the operation of the Company may and probably will vary from the following financial models or projections; and such variations may be material. The Company’s performance and the Company’s ability to meet its objectives, as described in our materials, may be affected by many factors, including numerous factors that are beyond the Company’s control.

The pitch deck and business plan is not a static document but rather a continuing process which changes over time. It should be anticipated that the Company’s business, operations, management, financial condition, and pitch decks will change during the course of the Company’s operations. The projected financial information in these materials was not prepared to comply with guidelines of the Securities and Exchange Commission or the American Institute of Certified Public Accountants. The projections are not intended to follow generally accepted accounting principles. Neither our accountants nor our legal counsel have compiled, audited, prepared or contributed to the projections or the underlying assumptions. None of these parties express an opinion with respect to the projections.

Confidential